After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...

The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments ...

Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket.

The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

The appointment of Pazdur as CDER head comes shortly after the surprise ousting of George Tidmarsh and should quiet many of ...

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a ...

Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.

Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as ...